HB3686 amends the Illinois Controlled Substances Act to add any compound containing gonadotropin-releasing hormone analogs to Schedule V of the state’s controlled substances list. Schedule V is the least restrictive controlled-substances category under Illinois law, but placing a substance in that schedule still subjects it to state regulation, including rules governing manufacture, distribution, dispensing, and possession.
The bill is narrowly drafted and does not create a new regulatory program beyond the scheduling change. Its practical effect would be to classify products containing gonadotropin-releasing hormone analogs as controlled substances under Illinois law, which would affect pharmacies, prescribers, manufacturers, distributors, and law enforcement by bringing those compounds under the Controlled Substances Act’s compliance and enforcement framework.
Impact
If enacted, HB3686 would amend Section 212 of the Illinois Controlled Substances Act, expanding Schedule V to include compounds containing gonadotropin-releasing hormone analogs. This would make those compounds subject to the state’s controlled-substance registration, handling, recordkeeping, and enforcement provisions applicable to Schedule V drugs, while leaving the rest of the Act unchanged.
Sentiment
Based on the available record, there is no committee transcript or vote history showing debate, support, or opposition, so the bill’s sentiment cannot be measured from legislative discussion. The caption and text suggest a technical drug-scheduling measure rather than a broad policy overhaul, which often indicates a limited and specialized policy focus.
Contention
No specific points of contention are documented in the provided materials because there are no committee transcripts or recorded votes. Potential areas of concern, if raised later, would likely involve whether gonadotropin-releasing hormone analogs should be treated as controlled substances at all, and whether the Schedule V classification is appropriate for the compounds affected.
Controlled substances: other; sentencing guidelines for retail sale of products containing ephedrine or pseudoephedrine; modify. Amends sec. 13m, ch. XVII of 1927 PA 175 (MCL 777.13m). TIE BAR WITH: HB 4947'25